Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
| The structure diagram of CVL006 and AK112. (A) CVL006. (B) AK112 ...
Antibody Structure and Function: The Basis for Engineering Therapeutics
Structure and Dynamics Guiding Design of Antibody Therapeutics and Vaccines
曾 50 亿美元出海：康方生物 AK112 国内报上市_Insight_临床_数据
A novel bispecific antibody CVL006 superior to AK112 for dual targeting ...
AK112（PD-1/VEGF）临床数据汇总 AK112 是 康方生物 自主研发，全球行业内首个进入临床研究的PD-1/VEGF双特异性抗体 ...
康方生物 - Akeso, Inc | SITC 2022速递 | PD-1/VEGF双抗AK112临床前研究成果首次发布
521 AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF ...
康方生物 - Akeso, Inc | 依达方® PD-1/VEGF双抗，依沃西单抗注射液
1194 Mechanism of action of ivonescimab (AK112/SMT112): a first-in ...
Akeso, Inc | Technology Platform
Akeso, Inc | 依达方® PD-1/VEGF bispecific, Ivonescimab injection
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti ...
从16种双抗产品的上市顺序、获批适应症及历年销售看双抗结构的演变_生物器材网
Unveiling the Synergistic Potential: Bispecific Antibodies in ...
Frontiers | Bispecific antibody for lung cancer: mechanisms and ...
AK112, a novel PD-1/VEGF bispecific antibody, in combination with ...
Abstract B123: Mechanism of action of ivonescimab (AK112/SMT112): a ...
康方生物 - Akeso, Inc | 张力教授团队PD-1/VEGF双抗（AK112）治疗肺癌最新临床研究结果在《柳叶刀》子刊发布
免疫联合抗血管生成治疗,免疫联合靶向的靶免"双抗"药AK112惊艳亮相CSCO大会_全球肿瘤医生网
Frontiers | A Novel Bispecific Antibody Targeting PD-L1 and VEGF With ...
Breakthrough Approval for AK112: Akeso Biopharma's $5 Billion Licensing ...
双抗降维打击？康方生物AK112头对头挑战K药|康方生物_新浪财经_新浪网
Engineering Monoclonal Antibodies for Improved Efficacy and Safety ...
Design of a fragment crystallizable-engineered tetravalent bispecific ...
50亿美元买AK112的Summit，是什么来头？|美元_新浪财经_新浪网
IASLC on Twitter: "Dr. Shun Lu presents a Phase Ib Study of AK112, a ...
smmt-20221231
AK112在CRC的进展将有望再造一个康方_腾讯新闻
Design and Production of Bispecific Antibodies
PK/PD properties of BI 836880, a vascular endothelial growth factor ...
Design and Characterization of Bispecific and Trispecific Antibodies ...
Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated ...
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
How Bispecific Antibodies Are Changing the Treatment of Complex Diseases
Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an ...
Current Indications and Future Landscape of Bispecific Antibodies for ...
The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From ...
A Bispecific, Tetravalent Antibody Targeting Inflammatory and ...
康方生物AK112优势地位不再 后线治疗耐药NSCLC数据低于预期 | 2024ASCO|康方生物_新浪财经_新浪网
Is Chlorine an Acid or Base?
Comprehensive Guide to Bispecific Antibodies: Formats, Recombinant ...
Biomolecules | Free Full-Text | Bispecific Antibodies and Antibody–Drug ...
Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy ...
Computer-Aided Identification of Kinase-Targeted Small Molecules for ...
中国创新药重大里程碑！康方生物双抗新药AK112以50亿美元授权给Summit
Bispecific Antibodies Expose Tumors to New Lines of Attack
Bispecific Antibody Formats
一线治疗NSCLC，康方生物PD-1/VEGF双抗AK112获CDE突破性疗法 - 知乎
认识治疗肺癌的双抗药物依沃西单抗_肺癌_肺癌治疗方式 - 好大夫在线
开卷考试，揭示AK112的HARMONI-2的OS数据必然成功|化疗|康方|脑转移
2021CSCO│AK112(PD-1/VEGF双抗)联合化疗一线治疗晚期NSCLC初露锋芒 AK112是康方自主研发的对称IgG1-ScFv ...
AK112联用辉瑞的ADC是最佳选择吗？ $康方生物(09926)$ $康宁杰瑞制药-B(09966)$ 康方生物 年报解读：夏博士说康方的 ...
$康方生物-B(09926)$ 头对头K药！PD-1/VEGF双抗AK112治疗晚期NSCLC的Ⅲ期临床试验已启动原创 ... - 雪球
双抗降维打击？康方生物AK112头对头挑战K药_手机新浪网
康方生物AK112联合AK117获批开展治疗恶性肿瘤的临床研究 12月31日，根据CDE官网， 康方生物 1类生物制药AK112和AK117 ...
依沃西单抗AK112——卓越生物技术公司的平凡之路 - 知乎
依沃西单抗（AK112）肺癌适应症的临床进展更新 依沃西单抗（AK112）肺癌适应症的临床进展更新一、 依沃西单抗临床研究覆盖NSCLC全部 ...
简析康方生物AK112+AK117对MSS CRC治疗的迭代潜力__财经头条__新浪财经
AK112是人源化
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid ...
康方生物前后周五判若两物，前周五AK112崩塌，后周五依沃西头对头优于K药_财富号_东方财富网
$康方生物-B(09926)$ 免疫双抗肺癌I期/II期临床研究进展、III期研发布局汇总。AK112和MEDI5752... - 雪球
Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress ...
When three is not a crowd: trispecific antibodies for enhanced cancer ...
康方生物AK112号称的肺癌五大临床，君实生物PD-1即将全部实现 $康方生物-B(09926)$ AK112在肺癌领域启动了五大临床。包括5 ...
缓解率100％！双特异性抗体AK112招募EGFR-TKI治疗失败的肺癌患者！ - 知乎
PD-1/VEGF双抗AK112（依沃西单抗）治疗非小细胞肺癌的临床数据
康方生物PD-1/VEGF双抗拟纳入优先审评_财富号_东方财富网
重磅！AK112治疗实体瘤研究结果出炉！疾病控制率达63.8%！
张力教授团队PD-1/VEGF双抗（AK112）治疗肺癌最新临床研究结果在《柳叶刀》子刊发布医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
大涨272%！免疫治疗革新基药诞生！AK112对比帕博利珠1L治疗PD-L1阳性NSCLC的III期临床获决定性胜出阳性结果医药新闻 ...
Summit亮相JPM，上个月50亿美元引进康方PD-1/VEGF双抗医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
获批上市！康方生物回应：AK112数据结果不存在低于预期医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
双抗+双抗！康方生物开展AK104联合AK112治疗NSCLC临床医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
免疫双抗药AK112治疗小细胞肺癌，80%的患者病灶大幅度缩小！医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
AK112/87 | AK MUR - Braydenmaine AAC Flashhider - Valkyrie X… | Flickr
康方生物AK112临床试验,抗PD-1和VEGF双特异性抗体AK112联合PARP抑制剂治疗复发性卵巢癌的Ib/II期临床研究
